P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Dan T. Vogl,Edward A. Stadtmauer,Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,David Irwin,Thierry Facon,Jean-Luc Harousseau,Anthony Boral,Rachel Neuwirth,Kenneth C. Anderson +10 more
TL;DR: This subgroup analysis of the phase III APEX trial examined whether prior exposure to specific therapies affected the relative efficacy of bortezomib versus dexamethasone in relapsed/refractory myeloma, and confirmed the superiority of bortsomib over dexamETH as well as time to progression and overall survival.
Journal ArticleDOI
Prevention and Treatment of Hepatic Venocclusive Disease after High-Dose Cytoreductive Therapy
TL;DR: The purpose of this review is to discuss the manifestations and pathophysiology of VOD and the options for prevention and treatment.
Journal ArticleDOI
Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
Paul G. Richardson,Brandon M. Triplett,Vincent T. Ho,Nelson J. Chao,Fiona L Dignan,Michelle E. Maglio,Mohamad Mohty +6 more
TL;DR: Defibrotide appears to protect endothelial cells and restore the thrombolytic–fibrinolytic balance and has demonstrated favorable Day +100 survival and overall adverse-event rates that seem similar to control groups receiving supportive care alone.
Journal ArticleDOI
IgM myeloma: A multicenter retrospective study of 134 patients
Jorge J. Castillo,Artur Jurczyszyn,Lucie Brozova,Edvan de Queiroz Crusoe,Jacek Czepiel,Julio Dávila,Angela Dispenzieri,Marion Eveillard,Mark A. Fiala,Irene M. Ghobrial,Alessandro Gozzetti,Joshua Gustine,Roman Hájek,Vania Hungria,Jiri Jarkovsky,David Jayabalan,Jacob P. Laubach,Barbara Lewicka,Vladimir Maisnar,Elisabet E. Manasanch,Philippe Moreau,Elizabeth A. Morgan,Hareth Nahi,Ruben Niesvizky,Claudia E. Paba-Prada,Tomas Pika,Ludek Pour,John L. Reagan,Paul G. Richardson,Jatin P. Shah,Ivan Spicka,Ravi Vij,Anna Waszczuk-Gajda,Morie A. Gertz +33 more
TL;DR: Patients with IgM myeloma present with similar characteristics and outcomes as patients with more commonMyeloma subtypes, and higher ISS score was associated with worse survival.
Journal ArticleDOI
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.
Douglas W. McMillin,Jake Delmore,Joseph Negri,Leutz Buon,Hannah M. Jacobs,Jacob P. Laubach,Jana Jakubikova,Melissa G. Ooi,Patrick Hayden,Robert L. Schlossman,Nikhil C. Munshi,Nikhil C. Munshi,Christoph Lengauer,Paul G. Richardson,Kenneth C. Anderson,Constantine S. Mitsiades +15 more
TL;DR: In this article, the small molecule heterocyclic compound NVP-LCQ195/AT9311 (LCQ 195) was used to induce cell cycle arrest and eventual apoptotic cell death of MM cells.